TactiFlex™ Ablation Catheter, Sensor Enabled™, TactiSys™ Quartz Equipment, TactiSys™ Quartz, TactiFlex™ Radiofrequency C

FDA premarket approval P220013 · Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation

PMA numberP220013

Approval

Applicant
Abbott Medical
Received
August 15, 2022
Decision date
May 18, 2023 (APPR)
Supplements
31, latest September 4, 2026
Product code
OAE – Catheter, Percutaneous, Cardiac Ablation, For Treatment Of Atrial Fibrillation

Official FDA PMA record

Approval order statement

Approval for the TactiFle Ablation Catheter, Sensor Enabled. This device is indicated for use in cardiac electrophysiological mapping and for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation and concomitant atrial flutter, when used in conjunction with a compatible RF generator and three-dimensional mapping system.